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During the last decade, the management of the patient with 
chronic congestive heart failure has undergone more dra- 
matic changes than nearly any other area in cardiovascular 
medicine. A wide variety of therapeutic options are now 
available to the clinician, and these have begun to challenge 
the most time-honored approaches to the treatment of fhis 
syndrome. For example, in the past we thought that bed rest 
was an important intervention in the management of chronic 
heart failure (I); we now believe that prolonged inactivity 
contributes importantly to the physical deconditioning and 
exercise intolerance seen in patients with this condition. In 
the past we believed that systemic perfusion pressures had 
to be supported in chronic heart failure to preserve organ 
function; we now routinely lower blood pressure in these 
patients with potent vasodilator drugs. In the past we 
thought that the administration of diiitalis was an essentiai 
part of any successful therdpeutic regimen for congestive 
heart failure (2,; we now worry about efficacy and safety of 
long-term inotropic interventions and even consider treating 
these patients with cardiodepressant drugs (for example, 
beta-adrenergic blocking agents)(3,4). 
Changes in the syndrome OF chmnic heart failure. Why 
has our view of heart failure changed so markedly during the 
last IO years? In part, our perspective has changed because 
the syndrome of chronic heart failure itself has changed, In 
the first half of this century, the most frequent causes of 
cdronic heart failure were hypertensive heart disease and 
valvular heart disease, most notably mitral stenosis. Conse- 
quently, physicians commonly viewed heart failure al a 
slowly evolving process that could remain compensated for 
decades. Arrhythmias were a frequent finding in these pa- 
tients, but mosl of the arrhythmias originated in Ihe atria; 
consequently, digitalis achieved widespread acceptance as a 
treatment for the syndrome, in part because of its unique 
ability lo control the ventricular response lo rapid atrial 
arrhythmias (5). Complaints ofdyspnea dominated the early 
chases of the disease. whereas comolaints of fatirme domi- 
ited the later phases. as signs of I& heart failure yielded 
nredictablv to sicns of rieht heart failure. The control of 
&iutn reiention-represened the primary therapeutic hal- 
lenge. Death commonly occurred after the development ofa 
pulmonary or cutaneous infection that resulted from the 
disruption oflocal defense mechanisms overwhelmed by the 
presence of tissue edema. Sudden death (except in patients 
with aortic stenosis) was uncommon. 
With the conlrol of rheumatic fever, valvular heart dis- 
ease as a cause of chronic heart failure has declined dramat- 
ically: this etiology now accounts for only 10% of patients 
referred lo centers for heart failure research. Left ventricular 
dysfunction has now become the most comnwtt cause of 
chronic heart failure, and in contrast o the experience of 20 
years ago, most affected patients are not hypertensive on 
presentation to the physician. What has accounted for this 
apparent shift in the cause af this syndrome? Coronary 
artery disease now represents the principal cause of chronic 
heart failure; we may be saving the lives of more patients 
during the acute phase of a myocardial infarction, but those 
who survive are now living with impaired ventricular func- 
tion. The prevalence of idiopathic dilated cardiomyopathy 
also appears 10 have increased significantly during the last 
decade, perhaps because of an increase in the incidence of 
viral myocarditis. This latter cause may become a dominant 
feature of the syndrome of heart failure in the future as a 
result of infection with the human immuncdeficiency virus. 
Regardless of the cause of left ventricular dysfunction, the 
course of congestive heart failure no longer unfolds over a 
period of decades. Advanced symptoms can develop in a 
period of hours or days or. at moct. over a period af months 
or a few years. It is now uncummun to bee patients who have 
had symptoms of heart failure for more than 5 to 8 yesrs. The 
contml of fluid retenlion is no longer the preeminent hera- 
peuticchallenge. Most patients with reiractury symptomsdo 
not have refractory edema. As in the past, arrhythmias 
remain a frequent finding in chronic hean failure. but now 
must of the arrhythmias originate in tbe ventrifles: atrial 
fibrillation is uncommon, being present in only IO to 15% cf 
patients. The progression from the syndrome of left heart 
failure to that of tieht heart failure is no lower inwitabk. 
because both &he& heart disease and idiopathic dilated 
cardiomyopathy can alicct the right and kit ventricles imul- 
taneously. In addition, as left ventricular function deterio- 
rates uver time, sudden death can unpredictably interrupt 
the course of the disease, frequently before the development 
of severe symptoms (6). 
Newer concepts in palhuphysiulogy of heart iaihtre. Be- 
cause the principal cause of congestive heart failure has 
changed during the past decade, we hme evolved a different 
understanding of the possible rule of the periphenl circula- 
tion in this disorder. In the decades during which mitral 
valve disease was a dominant cnuse of hean Failure. must 
attention was directed toward the state of the pulmonary 
vascda~ure as a major determinant of the clinical picture. 
Pulmonary vasoconstriction was believed to play a 
benejcial role in patients with mitral stenosis by reducing 
the rate of blood Row across the mitral valve and thereby 
lowering pulmonary venuus pressures (7). In fact, in the 
1950s and IY+Os, must endogenous mechanisms (including 
neurohotmonal mechanisms) were thought tu carry out 
imoortant adaptive functions in chronic heart failure. The 
sy&atbetic &rvous system was activated in these patients 
tu support cardiac contractility, and renin was released to 
suppml systemic blond pressure @,Y). Physicians were 
stmngly advised not to interfere with these endogenous 
compensatory systems because attempts to do so seemed tu 
produce serious adverse hemudynamic effects (IO). 
With the advent of left ventricular dvsfunclion as the 
major cause of heart failure, attention began to he directed 
toward the systemic (rather than the pulmonary) circulation 
us an important determinant of the clinical status of patients 
with this condition. If excessive systemic vasconstrictian 
contributed tu the development oicougcstive hear! failure in 
hypencnsive patients (II), it seemed reasonable to hypoth- 
esize that a similar pathophysiomgic process could exert a 
similar deleterious effect in the nwmotensive patient with 
advanced left ventricular dysfwction. Changes in the pe- 
ripheral circulation could limit systolic performance ia a 
fashion similar tu that seen in aortic stem&. When this 
marked syslemic vasoconstriction was counterxted phar- 
macologically by the use of direct-acting vasodilator drugs, 
patienlr with congesdve heart failure experienced ramatic 
hemodynamic benefits (12). 
‘f/w observation rhet vusodilofor drugs could produce 
immediare humxiynomic improvement in chronic heart fiil- 
ure proved to be the lint step in the realization that endog- 
cnous mechanisms were nut necessarily adaptive in these 
uatients but could ~Iav a deleterious role in this svudrome. 
&Id the prolon&d &iv&ion of neurohormon~ systems 
also exert long-term detrimental effects? If the release of 
neuruhannones could contribute to the pulmonary wocun- 
striction and right heart failure seen in mitral stenosis (I& 
cuuld neurohormonal activation also be responsible fur the 
marked systemic vasuconstciction in patients with heart 
failure resulting fmm left venttic& dysfunction? Early 
attempts to pharmacologically interfere with the major neu- 
rohomwnal systems (by blocking the alpha-adrenergic re- 
ceptor and the angiotensin II receptor) produced notable 
short-term hemudynamic benefits (14.15). More recent at- 
tempts to intermpt endogenous neumhomnmal mecimnisms 
(by inhibitingtheangiotensin-conveningenzymeorblocking 
the beta-adrencrgic receptor) produced long-term symptw 
matic improvement (16.17). When administered to severely 
ill patients. these neumhormooal antagonists improved left 
ventricular function, enhanced exercise toleruuce and re- 
duccd ruoliali~ (17, IX). Similar beneficial effects on exercise 
capacity and survival were seen when vasodilator dmen zd 
ne~ruh&monal antagunists were administered to patients 
with mild to moderate heart failure flY-211. As confidence in 
these therapeutic agents has grown, even asymptomatic 
patients with I& ventriculv dysfunction are being consid- 
ered potential candidates for treatment wlh vasedilators. 
converting enzyme inhibitors and beta-bbxken. 
Newer phanm,cd@ age& and appmad~es to manage. 
mea. These changesin the etialugy andpathophysiology of 
heart failure have been paralleled by a dramatic explosion in 
the synthesis and development of new pharmacologic agents 
for the treatment of this disorder. In the past. rncst advances 
in the phmmacothempy of congestive heart failure were 
based on the favorable respunses seen after the accidental 
ingestion of p&as or drugs used fur other medical condi- 
tions. Most therapeutic advances ‘25 years ago were 
achieved tbruwb an unoredictable orocess of trial and error. 
In cantmst, as-a resuli Oc new tec’huiques in clinical phw 
macology, chemists can now readily and rapidly design and 
synthesize scores of biily specific agents with precisely 
defined pharmacologic properties. More than 100 new eom- 
pounds have been synthesized and clinically tested for the 
treatment of chronic heart failure during the past 15 years. 
Not all of these new phammcologic developments have 
proved to be therapadically useful, however, and some have 
been suspected of producing deleterious effects. 
AN of rhere recent developments hove served TO challenge 
rrodirional views about the monogemenr of chronic hearf 
failure. Physicians now struggle to determine which of the 
approaches they previously accepted should be preserved 
and which should be discarded. They frequently ask: with 
the increasing acceptance of systemic vasodilators and con- 
verting enzy& inhibitors, should digitalis and diuretics still 
be considered first line therapy? Should we consider the 
benefits of the direct-acting vasodilators and the converting 
enzyme inhibitors with respect o survival to be equal, or are 
there additional benefits to be achieved by interfering with 
endogenous neurohormonal systems? If the systemic YBFO- 
dilators and the converting enzyme inhibitors reduce mor- 
tality resulting from progressive ventricular dysfunction 
(IQ, how should we prevent sudden death? Should we 
vigorously treat patients with serious (but asymptomatic) 
ventricular arrhythmias to prevent the subsequent occur- 
rence of lethal arrhythmias? Should we be concerned about 
drugs that can potentially enhance arrhythmias, such as the 
new inotropic drugs? These questions have evoked intense 
interest and controversy in the clinical community. 
Controverstal issues in management of heart fallwe. For- 
tunately, during the past 12 months. a great deal of new 
infomtation has become available that may help address 
these key questions. To present this infommtion in a cogent 
and balanced fashion to readers of the Journlrl of tkhc 
American College of Cardiulogy, we have asked some of the 
most vigorous protagorasts and antagonists of the four most 
controversial issues in the management of chronic heart 
failure to write a concise synopsis of recent evidence that 
supports their respective points of view. Two of the four 
controversies are discussed in this month’s issue of the 
Journal; the two remaining questions will be addressed in the 
next month‘s issue. Yet, even with this new information, ii is 
likely that no definitive answer to these controversies is 
possible at the present time. Furthermore. as additional data 
become available, as new concepts concerning the patho- 
physiology of heart failure evolve and as new therapeutic 
agents are synthesized, we should expect that even the most 
compelling argumeuts at the present time will require exten- 
sive revision in the future. 
The art of progress i  to prcscrve order amid change 
and to prerervc hange amid order. 
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